| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Gammagard Liquid vs Gammaked
Side-by-side clinical, coverage, and cost comparison for polyradiculoneuropathy, chronic inflammatory demyelinating.Deep comparison between: Gammagard Liquid vs Gammaked with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsGammaked has a higher rate of injection site reactions vs Gammagard Liquid based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Gammaked but not Gammagard Liquid, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Gammagard Liquid
Gammaked
At A Glance
IV infusion or SC injection
Every 3-4 weeks (IV) or weekly (SC)
Immune globulin replacement
IV infusion
Immune globulin
Indications
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Congenital agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
- Multifocal motor neuropathy
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Primary immune deficiency disorder
- Immune thrombocytopenic purpura
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Congenital agammaglobulinemia
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
Dosing
Primary Immunodeficiency (IV) 300-600 mg/kg every 3-4 weeks by IV infusion; start at 0.5 mL/kg/hr, increase every 30 minutes if tolerated up to 5 mL/kg/hr.
Primary Immunodeficiency (SC) Initial dose 1.37 x previous IV dose divided by weeks between IV doses, given weekly; 20-30 mL/site at 20-30 mL/hr/site (>=40 kg) or 20 mL/site at 15-20 mL/hr/site (<40 kg).
Multifocal Motor Neuropathy 0.5-2.4 g/kg/month by IV infusion; start at 0.5 mL/kg/hr, may increase if tolerated up to 5.4 mL/kg/hr.
Chronic Inflammatory Demyelinating Polyneuropathy Induction 2 g/kg divided over 2-5 consecutive days, then maintenance 1 g/kg divided over 1-4 consecutive days every 3 weeks by IV infusion; start at 0.5 mL/kg/hr, may increase if tolerated up to 5.4 mL/kg/hr.
Primary immune deficiency disorder IV: 300-600 mg/kg every 3-4 weeks; SC (PI only): individualized weekly dose calculated as previous IGIV dose (g) x 1.37 divided by number of weeks between IV doses.
Immune thrombocytopenic purpura IV only: total dose 2 g/kg given as 1 g/kg on two consecutive days or 0.4 g/kg on five consecutive days; do not administer subcutaneously.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating IV only: loading dose 2 g/kg over two to four consecutive days; maintenance 1 g/kg every 3 weeks (or 0.5 g/kg on two consecutive days every 3 weeks).
Contraindications
- Anaphylactic or severe systemic hypersensitivity to human immune globulin
- IgA deficiency with antibodies to IgA and history of hypersensitivity
- Previous anaphylactic or severe systemic reaction to human immune globulin
- IgA deficiency with antibodies against IgA and history of hypersensitivity reaction
Adverse Reactions
Most common (>=5%) - Primary Immunodeficiency (IV) Headache, fatigue, pyrexia, nausea, chills, rigors, pain in extremity, diarrhea, migraine, dizziness, vomiting, cough, urticaria, asthma, pharyngolaryngeal pain, rash, arthralgia, myalgia, edema peripheral, pruritus, cardiac murmur
Most common (>=5%) - Primary Immunodeficiency (SC) Infusion site events, headache, fatigue, heart rate increased, pyrexia, abdominal pain upper, nausea, vomiting, asthma, blood pressure systolic increased, diarrhea, ear pain, aphthous stomatitis, migraine, oropharyngeal pain, pain in extremity
Most common (>=5%) - Multifocal Motor Neuropathy Headache, chest discomfort, muscle spasms, muscular weakness, nausea, oropharyngeal pain, pain in extremity
Most common (>=5%) - Chronic Inflammatory Demyelinating Polyneuropathy Headache, pyrexia, anemia, leukopenia, neutropenia, illness, blood creatinine increased, dizziness, migraine, somnolence, tremor, nasal dryness, abdominal pain upper, vomiting, chills, nasopharyngitis, pain in extremity
Serious Aseptic meningitis (IV for PI), pulmonary embolism, blurred vision (MMN)
Postmarketing Hemolysis, anaphylactic shock, cerebrovascular accident, transient ischemic attack, tremor, myocardial infarction, deep vein thrombosis, hypotension, pulmonary embolism, pulmonary edema, hyperhidrosis, chest pain, transfusion-related acute lung injury, hypersensitivity, myalgia, chills
Most common (>=5%) PI (IV): cough, rhinitis, pharyngitis, headache, asthma, nausea, fever, diarrhea, sinusitis; PI (SC): local infusion site reactions, fatigue, headache, upper respiratory tract infection, arthralgia, diarrhea, nausea, sinusitis, bronchitis, depression, allergic dermatitis, erythema, migraine, myalgia, viral infection, pyrexia; ITP: headache, ecchymosis, vomiting, fever, nausea, rash, abdominal pain, back pain, dyspepsia; CIDP: headache, pyrexia, hypertension, chills, rash, nausea, arthralgia, asthenia
Serious Pulmonary embolism (CIDP), exacerbation of autoimmune pure red cell aplasia (PI), hemolytic anemia
Postmarketing Anaphylaxis, tachycardia, acute renal dysfunction/failure, ARDS, TRALI, pulmonary edema, cardiac arrest, thromboembolism, coma, seizures, aseptic meningitis, Stevens-Johnson syndrome, pancytopenia, hemolytic anemia, hepatic dysfunction
Pharmacology
GAMMAGARD LIQUID supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against bacterial and viral agents and contains antibodies that interact with immune system cells; the mechanism in CIDP may include immunomodulatory effects.
GAMMAKED is an immune globulin that supplies a broad spectrum of opsonic and neutralizing IgG antibodies against bacterial, viral, parasitic, and mycoplasmal agents and their toxins; the precise mechanism of action in ITP and CIDP has not been fully elucidated.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Gammagard Liquid
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (0/12)
Gammaked
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Gammagard Liquid
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Gammaked
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Gammagard Liquid
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Gammaked
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Gammagard Liquid.
No savings programs available for Gammaked.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Gammagard LiquidView full Gammagard Liquid profile
GammakedView full Gammaked profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.